Gynecologic cancer intergroup (GCIG) Consensus review for mucinous ovarian carcinoma

Jonathan A. Ledermann, Daniela Luvero, Aaron Shafer, Dennis O'Connor, Giorgia Mangili, Michael Friedlander, Jacobus Pfisterer, Mansoor R. Mirza, Jae Weon Kim, Jerome Alexandre, Amit Oza, Jubilee Brown

Research output: Contribution to journalReview articlepeer-review


Mucinous carcinomas of the ovary can be primary ormetastatic in origin. Improvements in the pathological diagnosis have increased the ability to distinguish between primary andmetastatic ovarian cancers and shown that primary mucinous carcinomas are a rare subtype of ovarian cancer. Most tumors are diagnosed at an early stage, and the prognosis after surgery is good. Advanced or recurrent mucinous carcinoma of the ovary responds poorly to current cytotoxic treatments, and the prognosis is poor. Here, we review the guidelines for surgery and the results of treatment of advanced and recurrent disease. Chemotherapy with platinum and paclitaxel is currently used to treat advanced disease, but the effect of these drugs is modest, and new treatments are needed.

Original languageEnglish
Pages (from-to)S14-S19
JournalInternational Journal of Gynecological Cancer
Issue number9
Publication statusPublished - Nov 1 2014


  • Mucinous ovarian cancer
  • Mucinous tumor

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology


Dive into the research topics of 'Gynecologic cancer intergroup (GCIG) Consensus review for mucinous ovarian carcinoma'. Together they form a unique fingerprint.

Cite this